Revvity HTRF Human Androgen Receptor Variant 7 Detection Kit, 500 Assay Points

The HTRF Androgen Receptor Variant 7 detection assay monitors the expression of the Androgen Receptor splice Variant 7 (AR-V7), providing insights into its presence, whether endogenous or overexpressed, within various cells.

The Androgen Receptor is a nuclear receptor that is activated by androgen hormones, including testosterone (T) and Dihydrotestosterone (DHT). Androgens bind to the ligand binding domain of the Androgen Receptor, resulting in receptor homodimerization and translocation to the nucleus. Downstream gene expression and signaling pathways are then activated, including the PI3K/AKT pathway. The gene expression induced by the Androgen Receptor promotes cell division, proliferation, differentiation, apoptosis, and angiogenesis. Dysregulation of the Androgen Receptor pathway can lead to oncogenic phenotypes, with Androgen Receptor activation or subexpression having been linked to conditions such as prostate cancer, breast cancer, glioblastoma, and other malignancies. Moreover, Androgen Receptor variants are expressed in various human cancer cell lines.

The Androgen Receptor Variant 7 (AR-V7) is a splice variant of the androgen receptor mRNA characterized by a truncated ligand-binding domain. It is constitutively active and widely expressed in human cancer cell lines. Among the AR-Vs described to date, AR-V7 is the most extensively evaluated and characterized, and several blood-based tests for AR-V7 have been developed.

Androgen Receptor and Variant 7 in particular has therefore become an important drug target for the pharmaceutical industry. The development of PROTAC compounds targeting the degradation of the Androgen Receptor is a popular therapeutic strategy to target Androgen Receptor-positive cancers.